Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy

  • Home
  • 2022
  • February
  • 16
  • Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy

Original Source

On February 16, 2022

Post navigation

Previous PostDistrict of Columbia Selects UnitedHealthcare to Administer District Dual Choice Program
Next PostExtra Space Storage Inc. Announces 1st Quarter 2022 Dividend

Related Post

May 23, 2022
  • Business News

Taiwan’s Tech Titans Adopt World’s First NVIDIA Grace CPU-Powered System Designs

May 23, 2022
  • Business News

GE Healthcare update on iodinated contrast media

May 23, 2022
  • Business News

Tyson Foods Announces Quarterly Dividend

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219